Canzonetta, C., Mulligan, C., Deutsch, S., Ruf, S., O'Doherty, A., Lyle, R., Borel, C., Lin-Marq, N., Delom, F., Groet, J., Schnappauf, F., De Vita, S., Averill, S., Priestley, J. V., Martin, J. E., Shipley, J., Denyer, G., Epstein, C. J., Fillat, C., Estivill, X., Tybulewicz, V. L. J., Fisher, E. M. C., Antonarakis, S. E., Nizetic, D. (2008) DYRK1A-dosage imbalance perturbs NRSF/REST levels, deregulating pluripotency and embryonic stem cell fate in Down syndrome. AMERICAN JOURNAL OF HUMAN GENETICS, 83 (3). pp. 388-400. ISSN 0002-9297

Full text not available from this repository.

Abstract

Down syndrome (DS) is the most common cause of mental retardation. Many neural phenotypes are shared between DS individuals and DS mouse models; however, the common underlying molecular pathogenetic mechanisms remain unclear. Using a transchromosomic model of DS, we show that a 30%-60% reduced expression of Nrsf/Rest (a key regulator of pluripotency and neuronal differentiation) is an alteration that persists in trisomy 21 from undifferentiated embryonic stem (ES) cells to adult brain and is reproducible across several DS models. Using partially trisomic ES cells, we map this effect to a three-gene segment of HSA21, containing DYRK1A. We independently identify the same locus as the most significant eQTL controlling REST expression in the human genome. We show that specifically silencing the third copy of DYRK1A rescues Rest levels, and we demonstrate altered Rest expression in response to inhibition of DYRK1A expression or kinase activity, and in a transgenic Dyrk1A mouse. We reveal that undifferentiated trisomy 21 ES cells show DYRK1A-dosesensitive reductions in levels of some pluripotency regulators, causing premature expression of transcription factors driving early endodermal and mesodermal differentiation, partially overlapping recently reported downstream effects of Rest +/-. They produce embryoid bodies with elevated levels of the primitive endoderm progenitor marker Gata4 and a strongly reduced neuroectodermal progenitor compartment. Our results suggest that DYRK1A-mediated deregulation of REST is a very early pathological consequence of trisomy 21 with potential to disturb the development of all embryonic lineages, warranting closer research into its contribution to DS pathology and new rationales for therapeutic approaches.

Item Type:	Article
Authors (ICR Faculty only):	Shipley, Janet
All Authors:	Canzonetta, C., Mulligan, C., Deutsch, S., Ruf, S., O'Doherty, A., Lyle, R., Borel, C., Lin-Marq, N., Delom, F., Groet, J., Schnappauf, F., De Vita, S., Averill, S., Priestley, J. V., Martin, J. E., Shipley, J., Denyer, G., Epstein, C. J., Fillat, C., Estivill, X., Tybulewicz, V. L. J., Fisher, E. M. C., Antonarakis, S. E., Nizetic, D.
Uncontrolled Keywords:	RESTRICTIVE SILENCER FACTOR; GENE-EXPRESSION VARIATION; REST/NRSF TARGET GENES; PROTEIN-KINASE; MOUSE MODEL; NEURONAL DEVELOPMENT; MENTAL-RETARDATION; IN-VIVO; REST; DYRK1A
Research teams:	ICR divisions > Cancer Therapeutics > Sarcoma Molecular Pathology ICR divisions > Molecular Pathology > Sarcoma Molecular Pathology
Depositing User:	Users 10 not found.
Date Deposited:	20 Oct 2008 09:01
Last Modified:	10 Feb 2010 11:51
URI:	http://publications.icr.ac.uk/id/eprint/7044

Actions (login required)

View Item